Nucleotide analog RNA polymerase inhibitor
This page covers all Nucleotide analog RNA polymerase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SARS-CoV-2 RNA polymerase, HCV NS5B RNA-dependent RNA polymerase, SARS-CoV-2 3CL protease; SARS-CoV-2 RNA-dependent RNA polymerase.
Targets
SARS-CoV-2 RNA polymerase · HCV NS5B RNA-dependent RNA polymerase · SARS-CoV-2 3CL protease; SARS-CoV-2 RNA-dependent RNA polymerase · Viral DNA polymerase
Marketed (3)
- Veklury · Gilead Sciences · Metabolic · 2200
Remdesivir is an antiviral nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2. - REMDESIVIR
- Sofosbuvir Oral Product · MTI University · Virology / Hepatology
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.
Phase 3 pipeline (3)
- Nirmatrelvir/ritonavir + remdesivir · UMC Utrecht · Infectious Disease / Virology
This combination uses nirmatrelvir/ritonavir to inhibit SARS-CoV-2 protease and remdesivir to inhibit viral RNA polymerase, targeting two critical steps of viral replication. - Cidofovir intravenous · Johns Hopkins Bloomberg School of Public Health · Infectious Disease / Virology
Cidofovir is a nucleotide analog that inhibits viral DNA polymerase, preventing viral DNA replication in infected cells. - Standard-of-care SARS-CoV-2 treatment · Chita State Regional Clinical Hospital Number 1 · Infectious Diseases
Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus.
Patent intelligence
- nucleotide analog patent landscape — aggregated cliff calendar, attackable patents, originator estates